Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 18

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 18
---
 million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the
StockBlock platform. The Offering did not include any warrants.

Investment
from Largest Shareholder

On
May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3
million in equity financing through a direct investment by
The Bayshore Trust, an entity affiliated with the Company’s largest shareholder (See Notes 4 and 5). In July 2025, an additional 666,666 common shares were issued for $2 million
received.

13

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The
following discussion and analysis should be read in conjunction with the Condensed Financial Statements and Notes thereto included elsewhere
in this Quarterly Report. This discussion contains certain forward-looking statements that involve risks and uncertainties. The Company’s
actual results and the timing of certain events could differ materially from those discussed in these forward-looking statements as a
result of certain factors, including, but not limited to, those set forth herein and elsewhere in this Quarterly Report and in the Company’s
other filings with the SEC. See “Cautionary Note Regarding Forward Looking Statements” below.

As
used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, unless otherwise indicated,
the terms “the Company”, “we”, “us”, “our” and similar terminology refer to Telomir Pharmaceuticals,
Inc.

Background
of the Company

Telomir-1
is a novel oral small molecule designed to regulate essential metal ions—such as iron, copper, and zinc—that are associated
with oxidative stress, telomere shortening, and cellular aging. By modulating these ions, Telomir-1 is intended to support metal homeostasis,
reduce oxidative imbalance, and help preserve telomere integrity. This approach is based on emerging research indicating that metal ion
dysregulation can accelerate oxidative stress and contribute to cellular decline. Preclinical studies have shown that Telomir-1 may influence
pathways involved in telomere maintenance and cellular protection, supporting its potential as a therapeutic candidate for further development
in age-related conditions.

To
date, we have not generated any revenue nor do we expect to generate revenue unless and until we successfully complete preclinical and
clinical development of, receive regulatory approval for, and commercialize a program and